circumsporozoite protein vaccine (modified Vaccinia Ankar Virus vector) (EMVI)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namecircumsporozoite protein vaccine (modified Vaccinia Ankar Virus vector) (EMVI)
Drug Alias NameMVA CSP
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsMalaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmarkUnited KingdomGambia
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEuropean Vaccine Initiative
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEuropean Vaccine InitiativeUniversity Of Oxford
Active IndicationsN/A
Inactive IndicationsMalaria

Other Information

ATC CodeN/A
Related LinksN/A